SCHEMBL12306352

SCHEMBL12306352

O=Cc1cnc2c(Br)cccn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
FEN1 P39748 1/20 0.38
ATM Q13315 1/20 0.38
TRIM24 O15164 2/20 0.37
TRIM33 Q9UPN9 2/20 0.37
KDM4E B2RXH2 3/20 0.33
GAA P10253 2/20 0.33
GLA P06280 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPT P10636 3/20 0.32
RECQL P46063 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
PTGER4 P35408 1/20 0.31
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
NFKB1 P19838 1/20 0.30
RAB9A P51151 1/20 0.30
NFKB2 Q00653 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20331206 0.82 ALDH1A1 (0.39) ALDH1A1ATMTRIM24TRIM33KDM4E
SCHEMBL5632902 0.81 MAPT (0.47) ALDH1A1TRIM24TRIM33KDM4EMAPT
SCHEMBL21387371 0.81 ALDH1A1 (0.38) ALDH1A1ATMTRIM24TRIM33KDM4E
SCHEMBL23498190 0.77 GAA (0.48) ALDH1A1TRIM24TRIM33GAASMN1; SMN2
SCHEMBL20294410 0.77 KDM4E (0.44) ALDH1A1FEN1ATMKDM4EGAA
SCHEMBL20294474 0.72 ALDH1A1 (0.52) ALDH1A1ATMKDM4EGAAHSD17B10
SCHEMBL20294389 0.72 LCK (0.34) ALDH1A1
SCHEMBL23089333 0.72 KDM4E (0.35) ALDH1A1FEN1KDM4EGAAGLA
SCHEMBL23320339 0.72 KDM4E (0.39) ALDH1A1FEN1KDM4EGAAGLA
SCHEMBL24632396 0.71 ATM (0.31) ALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 US disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
EP-2379552-B1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2014-02-26 EP disclosed
US-8546440-B2 Substituted bicyclic imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2013-10-01 US disclosed
US-8546440-B2 Substituted bicyclic imidazole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2013-10-01 US disclosed
US-20110237580-A1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS Janssen Pharmaceuticals, Inc. 2011-09-29 US disclosed
US-20110237580-A1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS Janssen Pharmaceuticals, Inc. 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C9, SSB, C1S ALDH1A1 3835/4885FEN1 2729/4885ATM 4536/4885
US-20110237580-A1 SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 ALDH1A1 2320/4885FEN1 3112/4885ATM 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.